Rinovitex

Rinovitex may be available in the countries listed below.

Ingredient matches for Rinovitex

Retinol

Retinol acetate (a derivative of Retinol) is reported as an ingredient of Rinovitex in the following countries:

• Spain

International Drug Name Search

Lansoprazol ActavisGroup

Lansoprazol ActavisGroup may be available in the countries listed below.

Ingredient matches for Lansoprazol ActavisGroup

Lansoprazole

Lansoprazole is reported as an ingredient of Lansoprazol ActavisGroup in the following countries:

• Netherlands

International Drug Name Search

Durezol

In the US, Durezol (difluprednate ophthalmic) is a member of the drug class ophthalmic steroids and is used to treat Postoperative Ocular Inflammation.

US matches:

• Durezol


• Durezol Emulsion

Ingredient matches for Durezol

Difluprednate

Difluprednate is reported as an ingredient of Durezol in the following countries:

• United States

International Drug Name Search

Walavin

Walavin may be available in the countries listed below.

Ingredient matches for Walavin

Griseofulvin

Griseofulvin is reported as an ingredient of Walavin in the following countries:

• India

International Drug Name Search

Ossopulvit D3 Madaus

Ossopulvit D3 Madaus may be available in the countries listed below.

Ingredient matches for Ossopulvit D3 Madaus

Calcium Carbonate

Calcium Carbonate is reported as an ingredient of Ossopulvit D3 Madaus in the following countries:

• Germany

Colecalciferol

Colecalciferol is reported as an ingredient of Ossopulvit D3 Madaus in the following countries:

• Germany

International Drug Name Search

Durabiotic

Durabiotic may be available in the countries listed below.

Ingredient matches for Durabiotic

Benzylpenicillin

Benzylpenicillin benzathine (a derivative of Benzylpenicillin) is reported as an ingredient of Durabiotic in the following countries:

• Israel

International Drug Name Search

Clotrex

Clotrex may be available in the countries listed below.

Ingredient matches for Clotrex

Clotrimazole

Clotrimazole is reported as an ingredient of Clotrex in the following countries:

• Bahrain

International Drug Name Search

Dakin Cooper

Dakin Cooper may be available in the countries listed below.

Ingredient matches for Dakin Cooper

Sodium Hypochlorite

Sodium Hypochlorite is reported as an ingredient of Dakin Cooper in the following countries:

• France

International Drug Name Search

Vocet

Vocet may be available in the countries listed below.

Ingredient matches for Vocet

Levocetirizine

Levocetirizine dihydrochloride (a derivative of Levocetirizine) is reported as an ingredient of Vocet in the following countries:

• Bangladesh

International Drug Name Search

Tazko

Tazko may be available in the countries listed below.

Ingredient matches for Tazko

Felodipine

Felodipine is reported as an ingredient of Tazko in the following countries:

• Belgium

Ramipril

Ramipril is reported as an ingredient of Tazko in the following countries:

• Belgium

International Drug Name Search

Larjanfilina

Larjanfilina may be available in the countries listed below.

Ingredient matches for Larjanfilina

Aminophylline

Aminophylline is reported as an ingredient of Larjanfilina in the following countries:

• Argentina

International Drug Name Search

Cetirizina Arrowblue

Cetirizina Arrowblue may be available in the countries listed below.

Ingredient matches for Cetirizina Arrowblue

Cetirizine

Cetirizine dihydrochloride (a derivative of Cetirizine) is reported as an ingredient of Cetirizina Arrowblue in the following countries:

• Portugal

International Drug Name Search

Cispa

Cispa may be available in the countries listed below.

Ingredient matches for Cispa

Cisplatin

Cisplatin is reported as an ingredient of Cispa in the following countries:

• Peru

International Drug Name Search

Deripil

Deripil may be available in the countries listed below.

Ingredient matches for Deripil

Erythromycin

Erythromycin is reported as an ingredient of Deripil in the following countries:

• Spain

International Drug Name Search

Cronitin

Cronitin may be available in the countries listed below.

Ingredient matches for Cronitin

Loratadine

Loratadine is reported as an ingredient of Cronitin in the following countries:

• Indonesia

International Drug Name Search

Cartisorb

Cartisorb may be available in the countries listed below.

Ingredient matches for Cartisorb

Glucosamine

Glucosamine sulfate (a derivative of Glucosamine) is reported as an ingredient of Cartisorb in the following countries:

• Spain

International Drug Name Search

Litiomal

Litiomal may be available in the countries listed below.

Ingredient matches for Litiomal

Lithium

Lithium carbonate (a derivative of Lithium) is reported as an ingredient of Litiomal in the following countries:

• Japan

International Drug Name Search

CoversylComp.Novum

CoversylComp.Novum may be available in the countries listed below.

Ingredient matches for CoversylComp.Novum

Indapamide

Indapamide is reported as an ingredient of CoversylComp.Novum in the following countries:

• Denmark


• Finland

Perindopril

Perindopril arginine (a derivative of Perindopril) is reported as an ingredient of CoversylComp.Novum in the following countries:

• Denmark


• Finland

International Drug Name Search

Kiniduron

Kiniduron may be available in the countries listed below.

Ingredient matches for Kiniduron

Quinidine

Quinidine hydrogen sulfate (a derivative of Quinidine) is reported as an ingredient of Kiniduron in the following countries:

• Finland

International Drug Name Search

Kalio chloridas GSK

Kalio chloridas GSK may be available in the countries listed below.

Ingredient matches for Kalio chloridas GSK

Potassium Chloride

Potassium Chloride is reported as an ingredient of Kalio chloridas GSK in the following countries:

• Lithuania

International Drug Name Search

Levistan GMP

Levistan GMP may be available in the countries listed below.

Ingredient matches for Levistan GMP

Lovastatin

Lovastatin is reported as an ingredient of Levistan GMP in the following countries:

• Venezuela

International Drug Name Search

Apo-Famotidine

Apo-Famotidine may be available in the countries listed below.

Ingredient matches for Apo-Famotidine

Famotidine

Famotidine is reported as an ingredient of Apo-Famotidine in the following countries:

• Canada


• Czech Republic


• Guyana


• Hungary


• Russian Federation


• Singapore


• Vietnam

International Drug Name Search

Methocaps

Methocaps may be available in the countries listed below.

Ingredient matches for Methocaps

Indometacin

Indometacin is reported as an ingredient of Methocaps in the following countries:

• South Africa

International Drug Name Search

Hidroxiurea Microsules

Hidroxiurea Microsules may be available in the countries listed below.

Ingredient matches for Hidroxiurea Microsules

Hydroxycarbamide

Hydroxycarbamide is reported as an ingredient of Hidroxiurea Microsules in the following countries:

• Argentina

International Drug Name Search

Sulfabrom

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Sulfabrom

Sulfabromomethazine

Sulfabromomethazine sodium (a derivative of Sulfabromomethazine) is reported as an ingredient of Sulfabrom in the following countries:

• United States

International Drug Name Search

CiloQuin

CiloQuin may be available in the countries listed below.

Ingredient matches for CiloQuin

Ciprofloxacin

Ciprofloxacin hydrochloride (a derivative of Ciprofloxacin) is reported as an ingredient of CiloQuin in the following countries:

• Australia

International Drug Name Search

Lansoprazol Genfar

Lansoprazol Genfar may be available in the countries listed below.

Ingredient matches for Lansoprazol Genfar

Lansoprazole

Lansoprazole is reported as an ingredient of Lansoprazol Genfar in the following countries:

• Colombia


• Ecuador


• Peru

International Drug Name Search

Alexcef

Alexcef may be available in the countries listed below.

Ingredient matches for Alexcef

Cefalexin

Cefalexin is reported as an ingredient of Alexcef in the following countries:

• Peru

International Drug Name Search

Fluclox Stragen

Fluclox Stragen may be available in the countries listed below.

Ingredient matches for Fluclox Stragen

Flucloxacillin

Flucloxacillin sodium salt (a derivative of Flucloxacillin) is reported as an ingredient of Fluclox Stragen in the following countries:

• Germany

International Drug Name Search

Lisinopril / Hydrochlorothiazid Alternova

Lisinopril/Hydrochlorothiazid Alternova may be available in the countries listed below.

Ingredient matches for Lisinopril/Hydrochlorothiazid Alternova

Hydrochlorothiazide

Hydrochlorothiazide is reported as an ingredient of Lisinopril/Hydrochlorothiazid Alternova in the following countries:

• Austria

Lisinopril

Lisinopril dihydrate (a derivative of Lisinopril) is reported as an ingredient of Lisinopril/Hydrochlorothiazid Alternova in the following countries:

• Austria

International Drug Name Search

Eugenol

Scheme

Ph. Eur.

CAS registry number (Chemical Abstracts Service)

0000097-53-0

Chemical Formula

C10-H12-O2

Molecular Weight

164

Therapeutic Categories

Antiseptic

Disinfectant

Anesthetic, local

Analgesic, topic

Chemical Names

2-Methoxy-4-(2-propenyl)-phenol

2-Methoxy-4-(prop-2-enyl)phenol (Ph. Eur.)

4-Allyl-2-methoxyphenol (USP)

Phenol, 2-methoxy-4-(2-propenyl)- (USP)

Foreign Names

• Eugenolum (Latin)
• Eugenol (German)
• Eugénol (French)
• Eugenol (Spanish)

Generic Names

• Eugénol (OS: DCF)
• 4-06-00-06337 (IS: Beilstein)
• 5-Allylguaiacol (IS)
• Allylguaiacol (IS)
• BRN 1366759 (IS)
• Caryophyllic acid (IS)
• CCRIS 306 (IS)
• Eugenic acid (IS)
• NSC 209525 (IS)
• Eugenol (PH: Ph. Eur. 6, BP 2010, USP 32)

Brand Names

• Alvogyl (Eugenol and Lidocaine)
  Septodont, France



• Iodopengha (Eugenol and Lidocaine)
  Biodica, France



• Neodyne (Eugenol and Zinc Oxide)
  Neo Dental Seiykau, Japan

International Drug Name Search

Glossary

DCF	Dénomination Commune Française
IS	Inofficial Synonym
OS	Official Synonym
PH	Pharmacopoeia Name
Ph. Eur.	European Pharmacopoeia
USP	Pharmacopoeia of the United States

Click for further information on drug naming conventions and International Nonproprietary Names.

Liposic

Liposic may be available in the countries listed below.

UK matches:

• Liposic
• Liposic (SPC)

Ingredient matches for Liposic

Carbomer

Carbomer is reported as an ingredient of Liposic in the following countries:

• Argentina


• Belgium


• France


• Germany


• Greece


• Hong Kong


• Ireland


• Netherlands


• Portugal


• Switzerland


• Tunisia


• United Kingdom

International Drug Name Search

Glossary

SPC	Summary of Product Characteristics (UK)

Click for further information on drug naming conventions and International Nonproprietary Names.

Meloxicam A

Meloxicam A may be available in the countries listed below.

Ingredient matches for Meloxicam A

Meloxicam

Meloxicam is reported as an ingredient of Meloxicam A in the following countries:

• Netherlands

International Drug Name Search

omalizumab Subcutaneous

oh-ma-LIZ-oo-mab

Subcutaneous route(Powder for Solution)

Anaphylaxis, presenting as bronchospasm, hypotension, syncope, urticaria, and/or angioedema of the throat or tongue, has been reported to occur after administration of omalizumab. Anaphylaxis may occur after the first dose or beyond 1 year after beginning omalizumab. Monitor patients closely after omalizumab administration and be prepared to manage life-threatening anaphylactic reactions .

Commonly used brand name(s)

In the U.S.

• Xolair

Available Dosage Forms:

• Powder for Solution

Therapeutic Class: Antiasthma

Pharmacologic Class: Monoclonal Antibody

Uses For omalizumab

Omalizumab injection is used to treat moderate to severe persistent allergic asthma. It is used when a patient's asthma has not been controlled sufficiently on other asthma medicines. omalizumab will not relieve an asthma attack that has already started.

Omalizumab is a medicine called an IgE blocker. IgE is short for immunoglobulin E. IgE is a substance that occurs naturally in the body in small amounts. This substance plays an important role in allergic asthma. When people with allergic asthma breathe in a year-round allergen, such as cat or dog dander, their bodies make more IgE. This may cause a series of reactions in your body that can lead to asthma attacks and symptoms. Omalizumab works by helping to block IgE.

omalizumab is available only with your doctor's prescription.

Before Using omalizumab

In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For omalizumab, the following should be considered:

Allergies

Tell your doctor if you have ever had any unusual or allergic reaction to omalizumab or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.

Pediatric

Appropriate studies have not been performed on the relationship of age to the effects of omalizumab injection in children younger than 12 years of age. Safety and efficacy have not been established.

Geriatric

Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of omalizumab injection in the elderly.

Pregnancy

	Pregnancy Category	Explanation
All Trimesters	B	Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate studies in pregnant women OR animal studies have shown an adverse effect, but adequate studies in pregnant women have failed to demonstrate a risk to the fetus.

Breast Feeding

There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.

Interactions with Medicines

Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. Tell your healthcare professional if you are taking any other prescription or nonprescription (over-the-counter [OTC]) medicine.

Interactions with Food/Tobacco/Alcohol

Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.

Proper Use of omalizumab

A nurse or other trained health professional will give you omalizumab. Omalizumab is given as a shot under your skin.

You will receive omalizumab once every 2 or 4 weeks. Your dose will be determined by your IgE level, which your doctor will measure with a simple blood test before treatment begins, and your body weight. Based on your dose, your doctor will also tell you if you will need 1, 2, or 3 injections per dose. If you need more than 1 injection, each will be given in a different place on your body.

Omalizumab is not a rescue medication and should not be used to treat sudden asthma attacks. It is not a substitute for the medicines you are already taking. Never suddenly stop taking, or change the dose of your inhaled steroids or any other asthma medicine you are taking unless your doctor tells you to do so.

omalizumab should come with a Medication Guide. Read and follow these instructions carefully. Ask your doctor if you have any questions.

Precautions While Using omalizumab

If you stop receiving omalizumab injections, your symptoms can be expected to return.

You may not see immediate improvement in your asthma after omalizumab treatment begins. It takes time for the medicine to work. It is important to continue your omalizumab injections until your doctor tells you otherwise.

omalizumab may cause a serious type of allergic reaction called anaphylaxis. Anaphylaxis can be life-threatening and requires immediate medical attention. Tell your doctor right away if you have a rash, cough, chest tightness, shortness of breath, trouble breathing, wheezing, lightheadedness, dizziness, fainting, rapid or weak heartbeat, anxiety, flushing, itching, hives, feeling warm, swelling of the throat or tongue, throat tightness, hoarseness, or trouble swallowing after receiving omalizumab.

A rare but serious condition called eosinophilia (increased white blood cells in the body) may occur while you are receiving this medication. A condition called vasculitis (inflammation of the blood vessels) may also be present. Eosinophilia can be serious and requires immediate medical attention. Tell your doctor right away if you have worsening lung symptoms, rash or bruising of the skin, fever, chest pain, or burning, tingling, or numbness in the hands and feet after receiving omalizumab.

Your doctor will ask you to remain at the healthcare facility or clinic for at least two hours after each injection to watch for immediate side effects that can be serious.

Using omalizumab may increase your risk of getting certain cancers or infections. Talk to your doctor if you have concerns about this risk.

Make sure any doctor or dentist who treats you knows that you are using omalizumab. omalizumab may affect the results of certain medical tests.

omalizumab Side Effects

Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur:

Rare

• Cough


• difficulty swallowing


• dizziness


• fast heartbeat


• hives


• itching


• malignant tumor


• puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue


• shortness of breath


• skin rash


• tightness in the chest


• unusual tiredness or weakness


• wheezing

Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More Common

• Bleeding


• blistering


• body aches or pain


• burning


• chills


• cold or flu-like symptoms


• coldness


• congestion


• discoloration of the skin


• dryness or soreness of the throat


• feeling of pressure


• fever


• headache


• hoarseness


• itching


• leg pain


• lumps


• muscle or joint pain


• numbness


• pain


• pain or tenderness around the eyes and cheekbones


• redness


• runny nose


• scarring


• shortness of breath or troubled breathing


• sore throat


• soreness


• stinging


• stuffy or runny nose


• swelling


• tender, swollen glands in the neck


• tenderness


• tingling


• trouble with swallowing


• ulceration


• voice changes


• warmth

Less common

• Arm pain


• blistering, crusting, irritation, itching, or reddening of the skin


• body produces substance that can bind to drug making it less effective or cause side effects


• cracked, dry, or scaly skin


• earache


• itching skin

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

See also: omalizumab Subcutaneous side effects (in more detail)

The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.

The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.

More omalizumab Subcutaneous resources

• Omalizumab Subcutaneous Side Effects (in more detail)
• Omalizumab Subcutaneous Use in Pregnancy & Breastfeeding
• Omalizumab Subcutaneous Drug Interactions
• Omalizumab Subcutaneous Support Group
• 9 Reviews for Omalizumab Subcutaneous - Add your own review/rating

Compare omalizumab Subcutaneous with other medications

• Asthma, Maintenance

Fentanyl WZF Polfa

Fentanyl WZF Polfa may be available in the countries listed below.

Ingredient matches for Fentanyl WZF Polfa

Fentanyl

Fentanyl is reported as an ingredient of Fentanyl WZF Polfa in the following countries:

• Vietnam

International Drug Name Search

Dextromethorphan/Guaifenesin/Phenylephrine Controlled-Release and Sustained-Release Tablets

Pronunciation: DEX-troe-meth-OR-fan/gwye-FEN-e-sin/FEN-ill-EF-rin
Generic Name: Dextromethorphan/Guaifenesin/Phenylephrine
Brand Name: Examples include Duraphen DM and Sinutuss DM

Dextromethorphan/Guaifenesin/Phenylephrine Controlled-Release and Sustained-Release Tablets are used for:

Relieving congestion, cough, and throat and airway irritation due to colds, flu, or hay fever. It may also be used for other conditions as determined by your doctor.

Dextromethorphan/Guaifenesin/Phenylephrine Controlled-Release and Sustained-Release Tablets are a decongestant, cough suppressant, and expectorant combination. It works by constricting blood vessels and reducing swelling in the nasal passages, loosening mucus and lung secretions in the chest, and making coughs more productive. The cough suppressant works in the brain to help decrease the cough reflex to reduce a dry cough.

Do NOT use Dextromethorphan/Guaifenesin/Phenylephrine Controlled-Release and Sustained-Release Tablets if:

• you are allergic to any ingredient in Dextromethorphan/Guaifenesin/Phenylephrine Controlled-Release and Sustained-Release Tablets


• you have an enlarged prostate gland, severe high blood pressure, rapid heartbeat, or other severe heart problems (eg, heart blood vessel disease)


• you have taken furazolidone or a monoamine oxidase inhibitor (MAOI) (eg, phenelzine) within the last 14 days

Contact your doctor or health care provider right away if any of these apply to you.

Before using Dextromethorphan/Guaifenesin/Phenylephrine Controlled-Release and Sustained-Release Tablets:

Some medical conditions may interact with Dextromethorphan/Guaifenesin/Phenylephrine Controlled-Release and Sustained-Release Tablets. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

• if you are pregnant, planning to become pregnant, or are breast-feeding


• if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement


• if you have allergies to medicines, foods, or other substances


• if you have a history of glaucoma, an enlarged prostate gland or other prostate problems, heart problems, diabetes, high blood pressure, blood vessel problems, adrenal gland problems, an overactive thyroid, seizures, or stroke


• if you have a chronic cough, lung problems (eg, asthma, chronic bronchitis, emphysema), or chronic obstructive pulmonary disease (COPD), or if cough occurs with large amounts of mucus

Some MEDICINES MAY INTERACT with Dextromethorphan/Guaifenesin/Phenylephrine Controlled-Release and Sustained-Release Tablets. Tell your health care provider if you are taking any other medicines, especially any of the following:

• Beta-blockers (eg, propranolol), catechol-O-methyltransferase (COMT) inhibitors (eg, tolcapone), furazolidone, indomethacin, MAOIs (eg, phenelzine), or tricyclic antidepressants (eg, amitriptyline) because they may increase the risk of Dextromethorphan/Guaifenesin/Phenylephrine Controlled-Release and Sustained-Release Tablets's side effects


• Digoxin or droxidopa because the risk of irregular heartbeat or heart attack may be increased


• Bromocriptine because the risk of its side effects may be increased by Dextromethorphan/Guaifenesin/Phenylephrine Controlled-Release and Sustained-Release Tablets


• Guanadrel, guanethidine, mecamylamine, methyldopa, or reserpine because their effectiveness may be decreased by Dextromethorphan/Guaifenesin/Phenylephrine Controlled-Release and Sustained-Release Tablets

This may not be a complete list of all interactions that may occur. Ask your health care provider if Dextromethorphan/Guaifenesin/Phenylephrine Controlled-Release and Sustained-Release Tablets may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use Dextromethorphan/Guaifenesin/Phenylephrine Controlled-Release and Sustained-Release Tablets:

Use Dextromethorphan/Guaifenesin/Phenylephrine Controlled-Release and Sustained-Release Tablets as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• Take Dextromethorphan/Guaifenesin/Phenylephrine Controlled-Release and Sustained-Release Tablets by mouth with or without food.


• Drink plenty of water while taking Dextromethorphan/Guaifenesin/Phenylephrine Controlled-Release and Sustained-Release Tablets.


• Swallow Dextromethorphan/Guaifenesin/Phenylephrine Controlled-Release and Sustained-Release Tablets whole. Do not break, crush, or chew before swallowing. Some brands of Dextromethorphan/Guaifenesin/Phenylephrine Controlled-Release and Sustained-Release Tablets may be broken in half before taking. If you have difficulty swallowing the whole tablet, ask your pharmacist if your brand of medicine may be broken in half.


• If you miss a dose of Dextromethorphan/Guaifenesin/Phenylephrine Controlled-Release and Sustained-Release Tablets, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Dextromethorphan/Guaifenesin/Phenylephrine Controlled-Release and Sustained-Release Tablets.

Important safety information:

• Dextromethorphan/Guaifenesin/Phenylephrine Controlled-Release and Sustained-Release Tablets may cause dizziness or drowsiness. These effects may be worse if you take it with alcohol or certain medicines. Use Dextromethorphan/Guaifenesin/Phenylephrine Controlled-Release and Sustained-Release Tablets with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.


• Do not take appetite suppressants while you are taking Dextromethorphan/Guaifenesin/Phenylephrine Controlled-Release and Sustained-Release Tablets without checking with your doctor.


• Dextromethorphan/Guaifenesin/Phenylephrine Controlled-Release and Sustained-Release Tablets has phenylephrine and dextromethorphan in it. Before you start any new medicine, check the label to see if it has phenylephrine or dextromethorphan in it too. If it does or if you are not sure, check with your doctor or pharmacist.


• Do NOT exceed the recommended dose or take Dextromethorphan/Guaifenesin/Phenylephrine Controlled-Release and Sustained-Release Tablets for longer than prescribed without checking with your doctor.


• If your symptoms do not improve within 5 to 7 days or if they become worse, check with your doctor.


• If cough persists for more than 1 week or comes back, or is accompanied by a fever, rash, or persistent headache, contact your health care provider. A persistent cough could be a sign of a serious condition.


• Dextromethorphan/Guaifenesin/Phenylephrine Controlled-Release and Sustained-Release Tablets may interfere with certain lab tests. Be sure your doctor and lab personnel know you are taking Dextromethorphan/Guaifenesin/Phenylephrine Controlled-Release and Sustained-Release Tablets.


• Tell your doctor or dentist that you take Dextromethorphan/Guaifenesin/Phenylephrine Controlled-Release and Sustained-Release Tablets before you receive any medical or dental care, emergency care, or surgery.


• Use Dextromethorphan/Guaifenesin/Phenylephrine Controlled-Release and Sustained-Release Tablets with caution in the ELDERLY; they may be more sensitive to its effects.


• Dextromethorphan/Guaifenesin/Phenylephrine Controlled-Release and Sustained-Release Tablets should not be used in CHILDREN younger than 2 years old; safety and effectiveness in these children have not been confirmed.


• PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Dextromethorphan/Guaifenesin/Phenylephrine Controlled-Release and Sustained-Release Tablets while you are pregnant. It is not known if Dextromethorphan/Guaifenesin/Phenylephrine Controlled-Release and Sustained-Release Tablets are found in breast milk. Do not breast-feed while taking Dextromethorphan/Guaifenesin/Phenylephrine Controlled-Release and Sustained-Release Tablets.

Possible side effects of Dextromethorphan/Guaifenesin/Phenylephrine Controlled-Release and Sustained-Release Tablets:

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Dizziness; excitability; headache; nausea; nervousness or anxiety; trouble sleeping; weakness.

Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); difficulty urinating; fast or irregular heartbeat; hallucinations; seizures; severe dizziness, lightheadedness, or headache; tremor.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

See also: Dextromethorphan/Guaifenesin/Phenylephrine side effects (in more detail)

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include blurred vision; confusion; hallucinations; seizures; severe dizziness, lightheadedness, or headache; severe drowsiness; unusually fast, slow, or irregular heartbeat; vomiting.

Proper storage of Dextromethorphan/Guaifenesin/Phenylephrine Controlled-Release and Sustained-Release Tablets:

Store Dextromethorphan/Guaifenesin/Phenylephrine Controlled-Release and Sustained-Release Tablets at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Dextromethorphan/Guaifenesin/Phenylephrine Controlled-Release and Sustained-Release Tablets out of the reach of children and away from pets.

General information:

• If you have any questions about Dextromethorphan/Guaifenesin/Phenylephrine Controlled-Release and Sustained-Release Tablets, please talk with your doctor, pharmacist, or other health care provider.


• Dextromethorphan/Guaifenesin/Phenylephrine Controlled-Release and Sustained-Release Tablets are to be used only by the patient for whom it is prescribed. Do not share it with other people.


• If your symptoms do not improve or if they become worse, check with your doctor.


• Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Dextromethorphan/Guaifenesin/Phenylephrine Controlled-Release and Sustained-Release Tablets. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Dextromethorphan/Guaifenesin/Phenylephrine resources

• Dextromethorphan/Guaifenesin/Phenylephrine Side Effects (in more detail)
• Dextromethorphan/Guaifenesin/Phenylephrine Use in Pregnancy & Breastfeeding
• Dextromethorphan/Guaifenesin/Phenylephrine Drug Interactions
• Dextromethorphan/Guaifenesin/Phenylephrine Support Group
• 0 Reviews for Dextromethorphan/Guaifenesin/Phenylephrine - Add your own review/rating

Compare Dextromethorphan/Guaifenesin/Phenylephrine with other medications

• Cough and Nasal Congestion

Nitrogesic

Nitrogesic may be available in the countries listed below.

Ingredient matches for Nitrogesic

Nitroglycerin

Nitroglycerin is reported as an ingredient of Nitrogesic in the following countries:

• India

International Drug Name Search

Decoquinate & Lincomycin

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Decoquinate & Lincomycin

Decoquinate

Decoquinate is reported as an ingredient of Decoquinate & Lincomycin in the following countries:

• United States

Lincomycin

Lincomycin is reported as an ingredient of Decoquinate & Lincomycin in the following countries:

• United States

International Drug Name Search

Doxepin-neuraxpharm

Doxepin-neuraxpharm may be available in the countries listed below.

Ingredient matches for Doxepin-neuraxpharm

Doxepin

Doxepin hydrochloride (a derivative of Doxepin) is reported as an ingredient of Doxepin-neuraxpharm in the following countries:

• Germany

International Drug Name Search

Levothroid

In the US, Levothroid (levothyroxine systemic) is a member of the drug class thyroid drugs and is used to treat Hashimoto's disease, Hypothyroidism - After Thyroid Removal, Myxedema Coma, Thyroid Suppression Test, TSH Suppression and Underactive Thyroid.

US matches:

• Levothroid

Ingredient matches for Levothroid

Levothyroxine

Levothyroxine sodium salt (a derivative of Levothyroxine) is reported as an ingredient of Levothroid in the following countries:

• Spain


• United States

International Drug Name Search

Prednisolon

Prednisolon may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Prednisolon

Mazipredone

Mazipredone hydrochloride (a derivative of Mazipredone) is reported as an ingredient of Prednisolon in the following countries:

• Russian Federation

Prednisolone

Prednisolone is reported as an ingredient of Prednisolon in the following countries:

• Ethiopia


• Finland


• Georgia


• Germany


• Hungary


• Lithuania


• Netherlands


• Norway


• Russian Federation


• Turkey

Prednisolone 21-(disodium phosphate) (a derivative of Prednisolone) is reported as an ingredient of Prednisolon in the following countries:

• Brazil

Prednisolone 21-acetate (a derivative of Prednisolone) is reported as an ingredient of Prednisolon in the following countries:

• Germany


• Netherlands

Prednisone

Prednisone 21-acetate (a derivative of Prednisone) is reported as an ingredient of Prednisolon in the following countries:

• Russian Federation

International Drug Name Search

Metronidazol Ges

Metronidazol Ges may be available in the countries listed below.

Ingredient matches for Metronidazol Ges

Metronidazole

Metronidazole is reported as an ingredient of Metronidazol Ges in the following countries:

• Spain

International Drug Name Search

Etynodiol

Scheme

Prop.INN

ATC (Anatomical Therapeutic Chemical Classification)

G03DC06

CAS registry number (Chemical Abstracts Service)

0001231-93-2

Chemical Formula

C20-H28-O2

Molecular Weight

300

Therapeutic Category

Progestin

Chemical Name

19-Norpregn-4-en-20-yne-3,17-diol, (3ß,17α)-

Foreign Names

• Etynodiolum (Latin)
• Etynodiol (German)
• Étynodiol (French)
• Etinodiol (Spanish)

Generic Names

• Ethynodiol (OS: BAN)
• Etinodiolo (OS: DCIT)
• Etynodiol (OS: BAN)
• Étynodiol (OS: DCF)
• Ethynodiol Diacetate (OS: USAN)
• Etynodiol Diacetate (OS: BANM)
• CB 8080 (IS)
• SC 11800 (IS)
• Ethynodiol Diacetate (PH: USP 32)
• Etynodiol Diacetate (PH: BP 2010)

Brand Names

• Demulen (Etynodiol and Ethinylestradiol)
  Pfizer, United States; GD Searle, United States; Pfizer, Canada



• Edulen (Etynodiol and Ethinylestradiol)
  Pfizer, Japan



• Femulen
  Pfizer, United Kingdom; Pfizer, Israel



• Kelnor (Etynodiol and Ethinylestradiol)
  Teva USA, United States



• Zovia (Etynodiol and Ethinylestradiol)
  Watson, United States

International Drug Name Search

Glossary

BAN	British Approved Name
BANM	British Approved Name (Modified)
DCF	Dénomination Commune Française
DCIT	Denominazione Comune Italiana
IS	Inofficial Synonym
OS	Official Synonym
PH	Pharmacopoeia Name
Prop.INN	Proposed International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Notix NF

Notix NF may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Notix NF

Clofenvinfos

Clofenvinfos is reported as an ingredient of Notix NF in the following countries:

• South Africa

International Drug Name Search

Beclophar

Beclophar may be available in the countries listed below.

Ingredient matches for Beclophar

Beclometasone

Beclometasone 17α,21-dipropionate (a derivative of Beclometasone) is reported as an ingredient of Beclophar in the following countries:

• Belgium

International Drug Name Search

Levoday

Levoday may be available in the countries listed below.

Ingredient matches for Levoday

Levofloxacin

Levofloxacin hemihydrate (a derivative of Levofloxacin) is reported as an ingredient of Levoday in the following countries:

• Myanmar

International Drug Name Search

Oxytetramix

Oxytetramix may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Oxytetramix

Oxytetracycline

Oxytetracycline hydrochloride (a derivative of Oxytetracycline) is reported as an ingredient of Oxytetramix in the following countries:

• Netherlands

International Drug Name Search

Thilodrin

Thilodrin may be available in the countries listed below.

Ingredient matches for Thilodrin

Dipivefrine

Dipivefrine hydrochloride (a derivative of Dipivefrine) is reported as an ingredient of Thilodrin in the following countries:

• Greece

International Drug Name Search

MPA

MPA may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for MPA

Medroxyprogesterone

Medroxyprogesterone 17α-acetate (a derivative of Medroxyprogesterone) is reported as an ingredient of MPA in the following countries:

• Australia

International Drug Name Search

Captopril Arrow

Captopril Arrow may be available in the countries listed below.

Ingredient matches for Captopril Arrow

Captopril

Captopril is reported as an ingredient of Captopril Arrow in the following countries:

• France

International Drug Name Search

Modécate

Modécate may be available in the countries listed below.

Ingredient matches for Modécate

Fluphenazine

Fluphenazine decanoate (a derivative of Fluphenazine) is reported as an ingredient of Modécate in the following countries:

• France

International Drug Name Search

Oseototal

Oseototal may be available in the countries listed below.

Ingredient matches for Oseototal

Calcitonin

Calcitonin is reported as an ingredient of Oseototal in the following countries:

• Spain

International Drug Name Search

Totacef

Totacef may be available in the countries listed below.

Ingredient matches for Totacef

Cefazolin

Cefazolin sodium salt (a derivative of Cefazolin) is reported as an ingredient of Totacef in the following countries:

• Estonia


• Serbia

International Drug Name Search

Angiomax

Angiomax is a brand name of bivalirudin, approved by the FDA in the following formulation(s):

ANGIOMAX (bivalirudin - injectable; intravenous)

• 
  Manufacturer: MEDICINES CO
  
  Approval date: December 15, 2000
  
  Strength(s): 250MG/VIAL ^[RLD]

Has a generic version of Angiomax been approved?

No. There is currently no therapeutically equivalent version of Angiomax available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Angiomax. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Inhibitors of thrombin
  Patent 5,196,404
  Issued: March 23, 1993
  Inventor(s): Maraganore; John M. & Fenton, II; John W. & Kline; Toni
  Assignee(s): Biogen, Inc.
  Health Research, Inc.
  This invention relates to novel biologically active molecules which bind to and inhibit thrombin. Specifically, these molecules are characterized by a thrombin anion-binding exosite association moiety (ABEAM); a linker portion of at least 18 .ANG. in length; and a thrombin catalytic site-directed moiety (CSDM). This invention also relates to compositions, combinations and methods which employ these molecules for therapeutic, prophylactic and diagnostic purposes.
  
  Patent expiration dates:
  
  
  • August 13, 2012
    
    ✓ 
    Patent use: INHIBITION OF THROMBIN IN A PATIENT
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • February 13, 2013
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Pharmaceutical formulations of bivalirudin and processes of making the same
  Patent 7,582,727
  Issued: September 1, 2009
  Inventor(s): Krishna; Gopal & Musso; Gary
  Assignee(s): The Medicinces Company
  Pharmaceutical batch(es) or pharmaceutical formulation(s) comprising bivalirudin as the active ingredient, and a method of preparing the pharmaceutical batch(es) or pharmaceutical formulation(s). The pharmaceutical batch(es) or pharmaceutical formulation(s) may have a maximum impurity level of Asp9-bivalirudin that does not exceed about 0.6%. Also, the pharmaceutical batch(es) or pharmaceutical formulation(s) may have a reconstitution time that does not exceed about 42 seconds. The method of preparing the pharmaceutical batch(es) or pharmaceutical formulation(s) may comprise dissolving bivalirudin in a solvent to form a first solution, efficiently mixing a pH-adjusting solution with the first solution to form a second solution in which the pH-adjusting solution may comprise a pH-adjusting solution solvent, and removing the solvent and the pH-adjusting solution solvent from the second solution.
  
  Patent expiration dates:
  
  
  • July 27, 2028
    
    ✓ 
    Drug product
  
  
  
  • January 27, 2029
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Pharmaceutical formulations of bivalirudin and processes of making the same
  Patent 7,598,343
  Issued: October 6, 2009
  Inventor(s): Krishna; Gopal & Musso; Gary
  Assignee(s): The Medicines Company
  Pharmaceutical batch(es) or pharmaceutical formulation(s) comprising bivalirudin as the active ingredient, and a method of preparing the pharmaceutical batch(es) or pharmaceutical formulation(s). The pharmaceutical batch(es) or pharmaceutical formulation(s) may have a maximum impurity level of Asp9-bivalirudin that does not exceed about 0.6%. Also, the pharmaceutical batch(es) or pharmaceutical formulation(s) may have a reconstitution time that does not exceed about 42 seconds. The method of preparing the pharmaceutical batch(es) or pharmaceutical formulation(s) may comprise dissolving bivalirudin in a solvent to form a first solution, efficiently mixing a pH-adjusting solution with the first solution to form a second solution in which the pH-adjusting solution may comprise a pH-adjusting solution solvent, and removing the solvent and the pH-adjusting solution solvent from the second solution.
  
  Patent expiration dates:
  
  
  • July 27, 2028
    
    ✓ 
    Drug product
  
  
  
  • January 27, 2029
    
    ✓ 
    Pediatric exclusivity
  
  

See also...

• Angiomax Consumer Information (Wolters Kluwer)
• Angiomax Consumer Information (Cerner Multum)
• Angiomax Advanced Consumer Information (Micromedex)
• Angiomax AHFS DI Monographs (ASHP)
• Bivalirudin Consumer Information (Wolters Kluwer)
• Bivalirudin Consumer Information (Cerner Multum)
• Bivalirudin Intravenous Advanced Consumer Information (Micromedex)
• Bivalirudin AHFS DI Monographs (ASHP)

Mixfard

Mixfard may be available in the countries listed below.

Ingredient matches for Mixfard

Insulin Injection, Soluble

Insulin Injection, Soluble human (a derivative of Insulin Injection, Soluble) is reported as an ingredient of Mixfard in the following countries:

• Ethiopia

International Drug Name Search

Biasetyl

Biasetyl may be available in the countries listed below.

Ingredient matches for Biasetyl

Estramustine

Estramustine 17ß-(disodium phosphate) (a derivative of Estramustine) is reported as an ingredient of Biasetyl in the following countries:

• Japan

International Drug Name Search

Orlev

Orlev may be available in the countries listed below.

Ingredient matches for Orlev

Levofloxacin

Levofloxacin is reported as an ingredient of Orlev in the following countries:

• Bangladesh

International Drug Name Search

Ipstyl

Ipstyl may be available in the countries listed below.

Ingredient matches for Ipstyl

Lanreotide

Lanreotide is reported as an ingredient of Ipstyl in the following countries:

• Italy

Lanreotide acetate (a derivative of Lanreotide) is reported as an ingredient of Ipstyl in the following countries:

• Denmark


• Iceland


• Italy


• Norway

International Drug Name Search

Gromax Anticoccidial Premix

Gromax Anticoccidial Premix may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Gromax Anticoccidial Premix

Maduramicin

Maduramicin is reported as an ingredient of Gromax Anticoccidial Premix in the following countries:

• Australia

Nicarbazin

Nicarbazin is reported as an ingredient of Gromax Anticoccidial Premix in the following countries:

• Australia

International Drug Name Search

Atropina Sulfato Ecar

Atropina Sulfato Ecar may be available in the countries listed below.

Ingredient matches for Atropina Sulfato Ecar

Atropine

Atropine sulfate (a derivative of Atropine) is reported as an ingredient of Atropina Sulfato Ecar in the following countries:

• Colombia

International Drug Name Search

Alfuzosine Winthrop

Alfuzosine Winthrop may be available in the countries listed below.

Ingredient matches for Alfuzosine Winthrop

Alfuzosin

Alfuzosin hydrochloride (a derivative of Alfuzosin) is reported as an ingredient of Alfuzosine Winthrop in the following countries:

• France


• Spain

International Drug Name Search

Pentoxifyllin

Pentoxifyllin may be available in the countries listed below.

Ingredient matches for Pentoxifyllin

Pentoxifylline

Pentoxifylline is reported as an ingredient of Pentoxifyllin in the following countries:

• Georgia

International Drug Name Search

Humuline Regular

Humuline Regular may be available in the countries listed below.

Ingredient matches for Humuline Regular

Insulin Injection, Soluble

Insulin Injection, Soluble human (a derivative of Insulin Injection, Soluble) is reported as an ingredient of Humuline Regular in the following countries:

• Belgium


• Luxembourg


• Netherlands

International Drug Name Search

Eurorapi

Eurorapi may be available in the countries listed below.

Ingredient matches for Eurorapi

Rabeprazole

Rabeprazole is reported as an ingredient of Eurorapi in the following countries:

• Vietnam

International Drug Name Search

Nodolfen

Nodolfen may be available in the countries listed below.

Ingredient matches for Nodolfen

Ibuprofen

Ibuprofen is reported as an ingredient of Nodolfen in the following countries:

• Spain

International Drug Name Search

Urandil

Urandil may be available in the countries listed below.

Ingredient matches for Urandil

Chlortalidone

Chlortalidone is reported as an ingredient of Urandil in the following countries:

• Czech Republic


• Slovakia

International Drug Name Search

Telithromycin

In the US, Telithromycin (telithromycin systemic) is a member of the drug class ketolides and is used to treat Bronchitis, Pneumonia, Sinusitis and Tonsillitis/Pharyngitis.

US matches:

• Telithromycin

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

J01FA15

CAS registry number (Chemical Abstracts Service)

0173838-31-8

Chemical Formula

C43-H65-N5-O10

Molecular Weight

812

Therapeutic Categories

Antibacterial: Macrolide

Antibacterial: Ketolide

Chemical Name

(3aS,4R,7R,9R,10R,11R,13R,15R,15aR)-4-Ethyloctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-1-[4-[4-(3-pyridyl)imidazol-1-yl]butyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-ß-Dxylo-hexapyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tet (WHO)

Foreign Names

• Telithromycinum (Latin)
• Telithromycin (German)
• Télithromycine (French)
• Telitromicina (Spanish)

Generic Names

• Telithromycin (OS: BAN, USAN)
• HMR 3647 (IS: HoechstMarion)
• Levviax (IS: Aventis)
• RU 647 (IS)
• RU 66647 (IS: HoechstMarion)

Brand Names

• Ketek
  Aventis, Bosnia & Herzegowina; Aventis, Poland; Aventis, Serbia; Aventis, Slovenia; Aventis, Slovakia; Aventis, Tunisia; Aventis Pharma S.A., Luxembourg; Aventis Pharma-F, Italy; Sanofi Aventis, Japan; Sanofi-Aventis, Austria; Sanofi-Aventis, Belgium; Sanofi-Aventis, Bahrain; Sanofi-Aventis, Brazil; Sanofi-Aventis, Canada; Sanofi-Aventis, Costa Rica; Sanofi-Aventis, Germany; Sanofi-Aventis, Ecuador; Sanofi-Aventis, Finland; Sanofi-Aventis, France; Sanofi-Aventis, United Kingdom; Sanofi-Aventis, Greece; Sanofi-Aventis, Croatia (Hrvatska); Sanofi-Aventis, Ireland; Sanofi-Aventis, Mexico; Sanofi-Aventis, Oman; Sanofi-Aventis, Romania; Sanofi-Aventis, Sweden; Sanofi-Aventis, Thailand; Sanofi-Aventis, Turkey; Sanofi-Aventis, Taiwan; Sanofi-Aventis, United States; Sanofi-Aventis, Venezuela; Sanofi-Aventis, South Africa; Sanofi-Aventis - Produtos farmacêuticos, S.A., Portugal; Sanofi-Aventis S.A.U., Spain

International Drug Name Search

Glossary

BAN	British Approved Name
IS	Inofficial Synonym
OS	Official Synonym
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name
WHO	World Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.

Naproxene sodico DOC

Naproxene sodico DOC may be available in the countries listed below.

Ingredient matches for Naproxene sodico DOC

Naproxen

Naproxen sodium salt (a derivative of Naproxen) is reported as an ingredient of Naproxene sodico DOC in the following countries:

• Italy

International Drug Name Search

Nabratin

Nabratin may be available in the countries listed below.

Ingredient matches for Nabratin

Clopidogrel

Clopidogrel hydrogen sulfate (a derivative of Clopidogrel) is reported as an ingredient of Nabratin in the following countries:

• Argentina

International Drug Name Search